Skip to content

Article

HMP Global Exploring Sale via Solomon Partners

Share on X (opens in a new window) Share on Facebook (opens in a new window) Share on LinkedIn (opens in a new window)
✨ Summary by AI at Octus
HMP Global, backed by Susquehanna Growth Equity, is conducting an auction process with Solomon Partners. The Malvern, Pennsylvania-based company, which generates approximately $75 million in EBITDA, specializes in organizing medical conferences and providing educational and market insights to pharmaceutical and medical device companies. HMP Global expanded its portfolio in 2025 through acquisitions, and its subsidiary, HMP Omnimedia, holds a first lien term loan maturing in July 2032. In the healthcare sector, senior direct lending facilities for M&A have seen a widening in average pricing, while other ongoing auctions include the sale processes for Health and Wellness Partners and Everest Clinical Research.

Susquehanna Growth Equity-backed HMP Global is running an auction process with Solomon Partners, according to sources.

The company generates roughly $75 million of EBITDA, the sources said.

Malvern, Penn.-based HMP produces medical conferences and provides continuing education and market insights to pharmaceutical and medical device companies. The company organizes more than 450 events annually, according to its website.

HMP has been a long-term hold for SGE, which originally invested in the business back in 2008, according to the sponsor’s website.

The company expanded its portfolio in 2025 through the acquisitions of Masterclasses in Dermatology, Psychiatry Redefined and Music City SCALE.

According to Octus’ BDC Database, the company’s subsidiary HMP Omnimedia has a first lien term loan priced at SOFR+525 bps that matures in July 2032. As of June 30, Sixth Street Lending Partners and Sixth Street Specialty Lending Inc. held a portion of the facility.

Senior direct lending facilities to back M&A in the healthcare sector widened to an average of about SOFR+509.4 bps in the second quarter of 2026 from about SOFR+492.2 bps in the first quarter, according to Octus’ Private Credit Dashboard.

Ongoing auctions in the sector include the Jefferies-led sale process for medical communications services provider Health and Wellness Partners, or HWP. Octus reported earlier this week that the process had reached the second round. The company generates roughly $25 million in EBITDA, as reported.

Elsewhere, Arlington Capital Partners is preparing to launch a sale process for contract research organization Everest Clinical Research in the fourth quarter, according to a Sept. 16 Octus report. Jefferies is acting as sell-side advisor to Everest, which will be marketed off close to $50 million in EBITDA, as reported.

Solomon Partners declined to comment. HMP and Susquehanna Growth Equity did not respond to requests for comment.

This publication has been prepared by Octus Intelligence, Inc. or one of its affiliates (collectively, "Octus") and is being provided to the recipient in connection with a subscription to one or more Octus products. Recipient’s use of the Octus platform is subject to Octus Terms of Use or the user agreement pursuant to which the recipient has access to the platform (the “Applicable Terms”). The recipient of this publication may not redistribute or republish any portion of the information contained herein other than with Octus express written consent or in accordance with the Applicable Terms. The information in this publication is for general informational purposes only and should not be construed as legal, investment, accounting or other professional advice on any subject matter or as a substitute for such advice. The recipient of this publication must comply with all applicable laws, including laws regarding the purchase and sale of securities. Octus obtains information from a wide variety of sources, which it believes to be reliable, but Octus does not make any representation, warranty, or certification as to the materiality or public availability of the information in this publication or that such information is accurate, complete, comprehensive or fit for a particular purpose. Recipients must make their own decisions about investment strategies or securities mentioned in this publication. Octus and its officers, directors, partners and employees expressly disclaim all liability relating to or arising from actions taken or not taken based on any or all of the information contained in this publication. © 2026 Octus. All rights reserved. Octus(TM) and the Octus logo are trademarks of Octus Intelligence, Inc.